Form 51-102F3
Material Change Report

Item 1 Name and Address of Company

Sennen Potash Corporation. (the **"Company"**)
Suite 800-1199 West Hastings Street
Vancouver, B.C. V6C 3T5

Item 2 Date of Material Change

November 20, 2018

Item 3 News Release

A news release was disseminated on December 3, 2018 through the facilities of Stockwatch.

Item 4 Summary of Material Change

The Company has entered into a binding share exchange agreement dated for reference November 19, 2018 with Folium Life Sciences Inc. ("**Folium**") and Folium's securityholders whereby the Company will acquire all of the issued and outstanding securities of Folium (the "**Transaction**").

Item 5 Full Description of Material Change

On November 20, 2018 the Company entered in a binding share exchange agreement with Folium and its securityholders in respect of the Transaction.

Pursuant to the Transaction, the Company will issue 93,700,000 common shares ("**Shares**") to the holders of common shares in the capital of Folium ("**Folium Shares**") at a deemed price of $0.40 per Share. The Transaction is an arm's length transaction. Upon the completion of the Transaction, it is expected that Folium will become a wholly-owned subsidiary of the Company (the "**Resulting Issuer**"). A finder's fee of 6,000,000 Shares is expected to be paid in connection with the Transaction to an arm's length third party.

In connection with the Transaction, the Company anticipates it will delist its common shares from the TSX Venture Exchange ("**TSXV**") and list the common shares on the Canadian Securities Exchange ("**CSE**").

Additionally, at closing of the Transaction, all of the current directors and officers of Sennen would resign in favor of nominees selected by Folium, being Fonda Betts, who will be appointed as Executive Chairman and Chad Clelland, who will also be appointed as President and Chief Executive Officer as well as three other additional nominees. Additional details concerning the remaining proposed board and management will be provided in a further press release regarding the Transaction.

Folium is a privately-held company and holds a license to produce cannabis under the *Cannabis Act* (Canada). On June 22, 2018 Folium was granted a cultivation license by Health Canada for its indoor facility located on Vancouver Island.

The Company intends to complete a non-brokered private placement offering of up to 7,500,000 subscription receipts (the "**Subscription Receipts**") at a price of $0.40 per Subscription Receipt. The Subscription Receipts would entitle the holder thereof to receive (without any further action or payment of any additional consideration) one unit ultimately of the Resulting Issuer (a "**Unit**"). Each Unit will consist of one common share and one-half of one common share purchase warrant. Each full warrant will entitle the holder to purchase an additional common share at the price of $0.80 per share for a period of 24 months from the closing of the Transaction. The net proceeds from the Financing will be used for the development of the Company's proposed business following its acquisition of Folium and for general working capital purposes

The closing of the Transaction is subject to a number of conditions, including: (i) completion of due diligence by the Company (ii) the completion of the Financing; (iii) receipt of all applicable regulatory approvals for the transaction including the approval of the CSE or the TSXV, as may be determined, for the listing of the Shares and, if applicable, of the TSXV for the delisting of Shares; (iv) Folium's license to produce shall not have been revoked or otherwise terminated; (v) no material adverse change shall have occurred in Folium or the Company; and (vi) other customary conditions for a transaction of this nature.

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

This Report is not being filed on a confidential basis in reliance on subsection 7.1(2) or (3) of National Instrument 51-102.

Item 7 Omitted Information

No information has been omitted on the basis that it is confidential information.

Item 8 Executive Officer

Brent Hahn is knowledgeable about the material change and the Report and may be contacted (604) 641-8993

Item 9 Date of Report

December 3, 2018